ClinicalTrials.gg
CompletedNCT00045032HERAUpdated Apr 27, 2017Results posted

Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer

A Phase 3 interventional study of Herceptin and Herceptin in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 203 sites in 33 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-27.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
5,099
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Enrollment
3rd of 366
5,099 · median 61
Started
2001
with 12 others
Phase 3
60 of 374
3 open now
Registered
29th of 374
by date
Lead sponsor
31 of 374
Hoffmann-La Roche

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 3rd largest by enrollment of the 366 interventional ones that give a count, is one of 13 that started in 2001, is one of 60 in phase 3, and was the 29th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this trial is to evaluate Herceptin treatment for 1 year and 2 years (versus observation/no Herceptin) in women with HER2-overexpressing primary breast cancer who have completed (neo-)adjuvant systemic chemotherapy, definitive surgery, and radiotherapy, if applicable. Efficacy and safety will be assessed for 10 years from randomization for each participant. All participants will continue to be followed for survival until 10 years after enrollment of the last participant.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non- primary invasive breast cancer overexpressing (determined by immunohistochemistry 3+ or positive fluorescence in situ hybridization test) that has been confirmed, adequately excised, axillary node positive or negative, and tumor size at least T1c according to Tumor/Node/Metastasis (TNM) staging
  • Completion of at least 4 cycles of (neo-) systemic chemotherapy, definitive surgery, and radiotherapy, if applicable
  • Known hormone receptor status
  • Baseline (LVEF) greater than or equal to (≥) 55 percent (%)

Exclusion criteria

Exclusion Criteria:

  • Prior invasive breast carcinoma
  • Other except for curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix
  • Clinical T4 tumors
  • Cumulative doxorubicin exposure greater than (>) 360 milligrams per meter-squared (mg/m\^2) or epirubicin >720 mg/m\^2 or any prior anthracyclines unrelated to the present breast cancer
  • Peripheral stem cell or bone marrow stem cell support
  • Prior mediastinal irradiation except for internal mammary node irradiation for the present breast cancer
  • Non-irradiated internal mammary nodes or supraclavicular lymph node involvement
  • Prior anti- therapy for any other reason or other prior biologic or immunotherapy for breast cancer
  • Concurrent anti-cancer treatment in another trial
  • Serious cardiac or pulmonary conditions/illness, or any other conditions that could interfere with planned treatment
  • Poor hematologic, hepatic, or renal function
  • Pregnancy or lactation
  • Women of or less than 1 year unwilling to use adequate measures
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
5,099 participants (actual)

Study arms

  • No intervention
    Observation Arm

    Participants who have completed definitive surgery and systemic adjuvant chemotherapy will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin will be provided.

  • Experimental
    Herceptin 1-Year Arm

    Participants who have completed definitive surgery and systemic adjuvant chemotherapy will receive Herceptin for 1 year or until disease recurrence, whichever occurs first. Participants will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.

    Drug: Herceptin

  • Experimental
    Herceptin 2-Year Arm

    Participants who have completed definitive surgery and systemic adjuvant chemotherapy will receive Herceptin for 2 years or until disease recurrence, whichever occurs first. Participants will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.

    Drug: Herceptin

Interventions

  • DrugTrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Herceptin will be given as a loading dose of 8 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks.

    Also known as: Trastuzumab

  • DrugTrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Herceptin will be given as a loading dose of 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks.

    Also known as: Trastuzumab

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Disease-Free Survival (DFS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up

    DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an Independent Data Monitoring Committee (IDMC) in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure.

    Time frame: From Baseline until time of event (median of 1 year)

  2. Percentage of Participants With DFS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up

    DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure.

    Time frame: From Baseline until time of event (median of 1 year)

  3. DFS Rate According to Kaplan-Meier Analysis in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up

    DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95 percent (%) confidence interval (CI) were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an IDMC in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure.

    Time frame: Year 2

  4. DFS Rate According to Kaplan-Meier Analysis in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up

    DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure.

    Time frame: Year 2

  5. Percentage of Participants With DFS Events Compared to Observation: 8-Year Median Follow-Up

    DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported.

    Time frame: From Baseline until time of event (median of 8 years)

  6. DFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up

    DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.

    Time frame: Year 3

  7. DFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up

    DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.

    Time frame: Year 5

  8. DFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up

    DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.

    Time frame: Year 7

  9. DFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up

    DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.

    Time frame: Year 8

  10. Percentage of Participants With DFS Events Compared to Observation: 10-Year Maximum Follow-Up

    DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported.

    Time frame: From Baseline until time of event (maximum of 10 years)

  11. DFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up

    DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.

    Time frame: Year 3

  12. DFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up

    DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.

    Time frame: Year 5

  13. DFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up

    DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.

    Time frame: Year 7

  14. DFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up

    DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.

    Time frame: Year 8

  15. DFS Rate at Year 9 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up

    DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.

    Time frame: Year 9

  16. DFS Rate at Year 10 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up

    DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.

    Time frame: Year 10

Secondary outcomes

  1. Percentage of Participants With DFS Events in 1-Year Versus 2-Year Herceptin: 10-Year Maximum Follow-Up

    DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported.

    Time frame: From Baseline until time of event (maximum of 10 years)

  2. DFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 10-Year Maximum Follow-Up

    DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.

    Time frame: Years 3, 5, 7, 8, 9, 10

  3. Percentage of Participants With Overall Survival (OS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up

    OS events referred to death from any cause. The percentage of participants who died was reported. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an IDMC in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure.

    Time frame: From Baseline until time of event (median of 1 year)

  4. Percentage of Participants With OS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up

    OS events referred to death from any cause. The percentage of participants who died was reported. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure.

    Time frame: From Baseline until time of event (median of 1 year)

  5. OS Rate According to Kaplan-Meier Analysis in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up

    OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an IDMC in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure.

    Time frame: Year 2

  6. OS Rate According to Kaplan-Meier Analysis in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up

    OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure.

    Time frame: Year 2

  7. Percentage of Participants With OS Events Compared to Observation: 8-Year Median Follow-Up

    OS events referred to death from any cause. The percentage of participants who died was reported.

    Time frame: From Baseline until time of event (median of 8 years)

  8. OS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up

    OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.

    Time frame: Years 3, 5, 7, 8

  9. Percentage of Participants With OS Events Compared to Observation: 11-Year Median Follow-Up

    OS events referred to death from any cause. The percentage of participants who died was reported.

    Time frame: From Baseline until time of event (median of 11 years)

  10. OS Rate According to Kaplan-Meier Analysis Compared to Observation: 11-Year Median Follow-Up

    OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with an 11-year median follow-up for OS events.

    Time frame: Years 3, 5, 7, 9, 10, 11, 12

  11. Percentage of Participants With OS Events in 1-Year Versus 2-Year Herceptin: 11-Year Median Follow-Up

    OS events referred to death from any cause. The percentage of participants who died was reported.

    Time frame: From Baseline until time of event (median of 11 years)

  12. OS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 11-Year Median Follow-Up

    OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with an 11-year median follow-up for OS events.

    Time frame: Years 3, 5, 7, 9, 10, 11, 12

  13. Percentage of Participants With Recurrence-Free Survival (RFS) Events Compared to Observation: 8-Year Median Follow-Up

    RFS events included local, regional, or distant tumor recurrence. The percentage of participants with at least one RFS event was reported.

    Time frame: From Baseline until time of event (median of 8 years)

  14. RFS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up

    RFS events included local, regional, or distant tumor recurrence. The percentage of participants free of RFS events (i.e., the RFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.

    Time frame: Years 3, 5, 7, 8

  15. Percentage of Participants With RFS Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up

    RFS events included local, regional, or distant tumor recurrence. The percentage of participants with at least one RFS event was reported.

    Time frame: From Baseline until time of event (median of 8 years)

  16. RFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up

    RFS events included local, regional, or distant tumor recurrence. The percentage of participants free of RFS events (i.e., the RFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.

    Time frame: Years 3, 5, 7, 8

  17. Percentage of Participants With Distant Disease-Free Survival (DDFS) Events Compared to Observation: 8-Year Median Follow-Up

    DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants with at least one DDFS event was reported.

    Time frame: From Baseline until time of event (median of 8 years)

  18. DDFS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up

    DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants free of DDFS events (i.e., the DDFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.

    Time frame: Years 3, 5, 7, 8

  19. Percentage of Participants With DDFS Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up

    DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants with at least one DDFS event was reported.

    Time frame: From Baseline until time of event (median of 8 years)

  20. DDFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up

    DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants free of DDFS events (i.e., the DDFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.

    Time frame: Years 3, 5, 7, 8

  21. Percentage of Participants With Tumor Recurrence (TR) Compared to Observation: 8-Year Median Follow-Up

    The percentage of participants with TR of the present breast cancer was reported. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy.

    Time frame: From Baseline until time of event (median of 8 years)

  22. TR-Free Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up

    The percentage of participants without TR of the present breast cancer (i.e., the TR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy.

    Time frame: Years 3, 5, 7, 8

  23. Percentage of Participants With TR in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up

    The percentage of participants with TR of the present breast cancer was reported. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy.

    Time frame: From Baseline until time of event (median of 8 years)

  24. TR-Free Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up

    The percentage of participants without TR of the present breast cancer (i.e., the TR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy.

    Time frame: Years 3, 5, 7, 8

  25. Percentage of Participants With Distant Tumor Recurrence (DTR) Compared to Observation: 8-Year Median Follow-Up

    The percentage of participants with DTR was reported. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy.

    Time frame: From Baseline until time of event (median of 8 years)

  26. DTR-Free Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up

    The percentage of participants without DTR (i.e., the DTR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy.

    Time frame: Years 3, 5, 7, 8

  27. Percentage of Participants With DTR in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up

    The percentage of participants with DTR was reported. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy.

    Time frame: From Baseline until time of event (median of 8 years)

  28. DTR-Free Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up

    The percentage of participants without DTR (i.e., the DTR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy.

    Time frame: Years 3, 5, 7, 8

  29. Percentage of Participants With Restricted Disease-Free Survival (RDFS) Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up

    RDFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer, or death from any cause. The percentage of participants with at least one RDFS event was reported.

    Time frame: From Baseline until time of event (median of 8 years)

  30. RDFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up

    RDFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer, or death from any cause. The percentage of participants free of RDFS events (i.e., the RDFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.

    Time frame: Years 3, 5, 7, 8

  31. Percentage of Participants With Primary Cardiac Endpoint Events Compared to Observation: 10-Year Maximum Follow-Up

    Primary cardiac endpoint events included the occurrence of any of the following between randomization and new therapy for recurrent disease: symptomatic New York Heart Association (NYHA) Class III or IV congestive heart failure (CHF) confirmed by a cardiologist with a drop in left ventricular ejection fraction (LVEF) at least 10 percentage points from Baseline and to a value less than (\<) 50%, and documentation of definite or probable cardiac death. Definite cardiac death included CHF, myocardial infarction, or primary arrhythmia. Probable cardiac death included unexpected sudden death within 24 hours of a cardiac event (syncope, cardiac arrest, chest pain, infarction, arrhythmia) without documented etiology. The percentage of participants with at least one primary cardiac endpoint event was reported. The 95% CI was calculated by the Pearson-Clopper method for a one-sample binomial.

    Time frame: From Baseline until time of event (maximum up to 10 years)

  32. Percentage of Participants With Secondary Cardiac Endpoint Events Compared to Observation: 10-Year Maximum Follow-Up

    Secondary cardiac endpoint events included NYHA Class I or II CHF with a drop in LVEF measured by multiple-gated acquisition or electrocardiogram, unless the subsequent assessment of LVEF indicated a return to levels that did not meet the definition of a significant LVEF drop. A significant LVEF drop was defined as an absolute reduction of at least 10 percentage points from Baseline and to a value \<50%. The percentage of participants with at least one secondary cardiac endpoint event was reported, excluding those with both a primary and secondary cardiac endpoint event. The 95% CI was calculated by the Pearson-Clopper method for a one-sample binomial.

    Time frame: From Baseline until time of event (maximum up to 10 years)

07

Results

Posted Apr 27, 2017

Participant flow

Participant flow — Overall Study
MilestoneObservation ArmHerceptin 1-Year ArmHerceptin 2-Year Arm
Started169717021700
Crossover to adjuvant herceptin88800
Completed834994974
Not completed863708726
Withdrew: Adverse event/intercurrent illness227
Withdrew: Death222417
Withdrew: Insufficient therapeutic response542437445
Withdrew: Violation of selection criteria at entry366
Withdrew: Other protocol violation201
Withdrew: Refused/did not cooperate/withdrew1429384
Withdrew: Failure to return576261
Withdrew: Other9384105

Outcome measures

PrimaryPercentage of Participants With Disease-Free Survival (DFS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up

DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an Independent Data Monitoring Committee (IDMC) in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure.

Time frame:
From Baseline until time of event (median of 1 year)
Reported as:
Number · percentage of participants
Percentage of Participants With Disease-Free Survival (DFS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year Arm
Percentage of Participants With Disease-Free Survival (DFS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up12.97.5
Statistical analysis
  • Observation Arm vs Herceptin 1-Year Arm · Log Rank · p = <0.0001
  • Observation Arm vs Herceptin 1-Year Arm · Hazard ratio (hr): 0.54 · 95% CI 0.44 to 0.67HR for Herceptin 1-Year Arm versus Observation Arm.
PrimaryPercentage of Participants With DFS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up

DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure.

Time frame:
From Baseline until time of event (median of 1 year)
Reported as:
Number · percentage of participants
Percentage of Participants With DFS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up
percentage of participantsObservation ArmHerceptin 2-Year Arm
Percentage of Participants With DFS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up13.07.6
Statistical analysis
  • Observation Arm vs Herceptin 2-Year Arm · Log Rank · p = 0.000
  • Observation Arm vs Herceptin 2-Year Arm · Hazard ratio (hr): 0.43 · 95% CI 0.34 to 0.53HR for Herceptin 2-Year Arm versus Observation Arm.
PrimaryDFS Rate According to Kaplan-Meier Analysis in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up

DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95 percent (%) confidence interval (CI) were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an IDMC in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure.

Time frame:
Year 2
Reported as:
Number · percentage of participants
DFS Rate According to Kaplan-Meier Analysis in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year Arm
DFS Rate According to Kaplan-Meier Analysis in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up78.18 (75 to 81)85.80 (83 to 89)
PrimaryDFS Rate According to Kaplan-Meier Analysis in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up

DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure.

Time frame:
Year 2
Reported as:
Number · percentage of participants
DFS Rate According to Kaplan-Meier Analysis in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up
percentage of participantsObservation ArmHerceptin 2-Year Arm
DFS Rate According to Kaplan-Meier Analysis in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up73.60 (70 to 77)87.50 (85 to 90)
PrimaryPercentage of Participants With DFS Events Compared to Observation: 8-Year Median Follow-Up

DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported.

Time frame:
From Baseline until time of event (median of 8 years)
Reported as:
Number · percentage of participants
Percentage of Participants With DFS Events Compared to Observation: 8-Year Median Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year ArmHerceptin 2-Year Arm
Percentage of Participants With DFS Events Compared to Observation: 8-Year Median Follow-Up33.627.727.8
Statistical analysis
  • Observation Arm vs Herceptin 1-Year Arm · Log Rank · p = <0.0001
  • Observation Arm vs Herceptin 1-Year Arm · Hazard ratio (hr): 0.76 · 95% CI 0.67 to 0.86HR for Herceptin 1-Year Arm versus Observation Arm.
  • Observation Arm vs Herceptin 2-Year Arm · Log Rank · p = <0.0001
  • Observation Arm vs Herceptin 2-Year Arm · Hazard ratio (hr): 0.75 · 95% CI 0.67 to 0.85HR for Herceptin 2-Year Arm versus Observation Arm.
PrimaryDFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up

DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.

Time frame:
Year 3
Reported as:
Number · percentage of participants
DFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year ArmHerceptin 2-Year Arm
DFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up75.2 (73.1 to 77.3)81.3 (79.4 to 83.2)83.5 (81.7 to 85.3)
PrimaryDFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up

DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.

Time frame:
Year 5
Reported as:
Number · percentage of participants
DFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year ArmHerceptin 2-Year Arm
DFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up70.0 (67.8 to 72.3)75.9 (73.8 to 78.0)76.5 (74.4 to 78.5)
PrimaryDFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up

DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.

Time frame:
Year 7
Reported as:
Number · percentage of participants
DFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year ArmHerceptin 2-Year Arm
DFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up66.0 (63.6 to 68.3)72.4 (70.2 to 74.6)72.5 (70.4 to 74.7)
PrimaryDFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up

DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.

Time frame:
Year 8
Reported as:
Number · percentage of participants
DFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year ArmHerceptin 2-Year Arm
DFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up64.8 (62.4 to 67.2)71.2 (69.0 to 73.4)71.0 (68.7 to 73.2)
PrimaryPercentage of Participants With DFS Events Compared to Observation: 10-Year Maximum Follow-Up

DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported.

Time frame:
From Baseline until time of event (maximum of 10 years)
Reported as:
Number · percentage of participants
Percentage of Participants With DFS Events Compared to Observation: 10-Year Maximum Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year ArmHerceptin 2-Year Arm
Percentage of Participants With DFS Events Compared to Observation: 10-Year Maximum Follow-Up35.829.730.5
Statistical analysis
  • Observation Arm vs Herceptin 1-Year Arm · Hazard ratio (hr): 0.76 · 95% CI 0.68 to 0.86HR for Herceptin 1-Year Arm versus Observation Arm.
  • Observation Arm vs Herceptin 2-Year Arm · Hazard ratio (hr): 0.77 · 95% CI 0.69 to 0.87HR for Herceptin 2-Year Arm versus Observation Arm.
PrimaryDFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up

DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.

Time frame:
Year 3
Reported as:
Number · percentage of participants
DFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year ArmHerceptin 2-Year Arm
DFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up75.2 (73.1 to 77.3)81.3 (79.4 to 83.2)83.4 (81.6 to 85.2)
PrimaryDFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up

DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.

Time frame:
Year 5
Reported as:
Number · percentage of participants
DFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year ArmHerceptin 2-Year Arm
DFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up70.0 (67.8 to 72.2)75.9 (73.8 to 78.0)76.4 (74.4 to 78.5)
PrimaryDFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up

DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.

Time frame:
Year 7
Reported as:
Number · percentage of participants
DFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year ArmHerceptin 2-Year Arm
DFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up65.8 (63.5 to 68.2)72.4 (70.2 to 74.5)72.5 (70.3 to 74.7)
PrimaryDFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up

DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.

Time frame:
Year 8
Reported as:
Number · percentage of participants
DFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year ArmHerceptin 2-Year Arm
DFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up64.7 (62.3 to 67.0)71.2 (69.0 to 73.4)70.7 (68.5 to 72.9)
PrimaryDFS Rate at Year 9 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up

DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.

Time frame:
Year 9
Reported as:
Number · percentage of participants
DFS Rate at Year 9 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year ArmHerceptin 2-Year Arm
DFS Rate at Year 9 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up63.5 (61.2 to 65.9)70.3 (68.1 to 72.6)69.2 (67.0 to 71.5)
PrimaryDFS Rate at Year 10 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up

DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.

Time frame:
Year 10
Reported as:
Number · percentage of participants
DFS Rate at Year 10 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year ArmHerceptin 2-Year Arm
DFS Rate at Year 10 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up62.5 (60.1 to 64.8)69.3 (67.0 to 71.5)68.5 (66.2 to 70.7)
SecondaryPercentage of Participants With DFS Events in 1-Year Versus 2-Year Herceptin: 10-Year Maximum Follow-Up

DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported.

Time frame:
From Baseline until time of event (maximum of 10 years)
Reported as:
Number · percentage of participants
Percentage of Participants With DFS Events in 1-Year Versus 2-Year Herceptin: 10-Year Maximum Follow-Up
percentage of participantsHerceptin 1-Year ArmHerceptin 2-Year Arm
Percentage of Participants With DFS Events in 1-Year Versus 2-Year Herceptin: 10-Year Maximum Follow-Up25.826.6
Statistical analysis
  • Herceptin 1-Year Arm vs Herceptin 2-Year Arm · Log Rank · p = 0.7962 · Hazard ratio (hr): 1.02 · 95% CI 0.89 to 1.17HR for Herceptin 2-Year Arm versus Herceptin 1-Year Arm.
SecondaryDFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 10-Year Maximum Follow-Up

DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.

Time frame:
Years 3, 5, 7, 8, 9, 10
Reported as:
Number · percentage of participants
DFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 10-Year Maximum Follow-Up
percentage of participantsHerceptin 1-Year ArmHerceptin 2-Year Arm
Year 386.7 (85.0 to 88.4)89.0 (87.4 to 90.6)
Year 581.0 (79.0 to 82.9)81.6 (79.6 to 83.5)
Year 777.2 (75.1 to 79.3)77.4 (75.3 to 79.5)
Year 875.9 (73.8 to 78.1)75.5 (73.3 to 77.7)
Year 975.0 (72.8 to 77.2)73.9 (71.7 to 76.1)
Year 1073.9 (71.7 to 76.1)73.1 (70.8 to 75.3)
SecondaryPercentage of Participants With Overall Survival (OS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up

OS events referred to death from any cause. The percentage of participants who died was reported. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an IDMC in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure.

Time frame:
From Baseline until time of event (median of 1 year)
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Survival (OS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year Arm
Percentage of Participants With Overall Survival (OS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up2.41.8
Statistical analysis
  • Observation Arm vs Herceptin 1-Year Arm · Log Rank · p = 0.2379
  • Observation Arm vs Herceptin 1-Year Arm · Hazard ratio (hr): 0.75 · 95% CI 0.47 to 1.21HR for Herceptin 1-Year Arm versus Observation Arm.
SecondaryPercentage of Participants With OS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up

OS events referred to death from any cause. The percentage of participants who died was reported. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure.

Time frame:
From Baseline until time of event (median of 1 year)
Reported as:
Number · percentage of participants
Percentage of Participants With OS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up
percentage of participantsObservation ArmHerceptin 2-Year Arm
Percentage of Participants With OS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up2.21.4
Statistical analysis
  • Observation Arm vs Herceptin 2-Year Arm · Log Rank · p = 0.003
  • Observation Arm vs Herceptin 2-Year Arm · Hazard ratio (hr): 0.47 · 95% CI 0.28 to 0.79HR for Herceptin 2-Year Arm versus Observation Arm.
SecondaryOS Rate According to Kaplan-Meier Analysis in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up

OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an IDMC in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure.

Time frame:
Year 2
Reported as:
Number · percentage of participants
OS Rate According to Kaplan-Meier Analysis in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year Arm
OS Rate According to Kaplan-Meier Analysis in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up94.98 (93 to 97)95.88 (94 to 98)
SecondaryOS Rate According to Kaplan-Meier Analysis in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up

OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure.

Time frame:
Year 2
Reported as:
Number · percentage of participants
OS Rate According to Kaplan-Meier Analysis in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up
percentage of participantsObservation ArmHerceptin 2-Year Arm
OS Rate According to Kaplan-Meier Analysis in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up94.39 (92 to 97)97.28 (96 to 98)
SecondaryPercentage of Participants With OS Events Compared to Observation: 8-Year Median Follow-Up

OS events referred to death from any cause. The percentage of participants who died was reported.

Time frame:
From Baseline until time of event (median of 8 years)
Reported as:
Number · percentage of participants
Percentage of Participants With OS Events Compared to Observation: 8-Year Median Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year ArmHerceptin 2-Year Arm
Percentage of Participants With OS Events Compared to Observation: 8-Year Median Follow-Up20.616.316.1
Statistical analysis
  • Observation Arm vs Herceptin 1-Year Arm · Log Rank · p = 0.0005
  • Observation Arm vs Herceptin 1-Year Arm · Hazard ratio (hr): 0.76 · 95% CI 0.65 to 0.88HR for Herceptin 1-Year Arm versus Observation Arm.
  • Observation Arm vs Herceptin 2-Year Arm · Log Rank · p = 0.0001
  • Observation Arm vs Herceptin 2-Year Arm · Hazard ratio (hr): 0.74 · 95% CI 0.63 to 0.86HR for Herceptin 2-Year Arm versus Observation Arm.
SecondaryOS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up

OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.

Time frame:
Years 3, 5, 7, 8
Reported as:
Number · percentage of participants
OS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year ArmHerceptin 2-Year Arm
Year 390.7 (89.3 to 92.1)92.7 (91.5 to 94.0)94.4 (93.3 to 95.6)
Year 584.5 (82.8 to 86.3)86.9 (85.2 to 88.5)88.7 (87.2 to 90.3)
Year 779.5 (77.5 to 81.5)83.9 (82.1 to 85.7)84.6 (82.9 to 86.4)
Year 877.4 (75.2 to 79.5)82.7 (80.8 to 84.6)82.4 (80.4 to 84.3)
SecondaryPercentage of Participants With OS Events Compared to Observation: 11-Year Median Follow-Up

OS events referred to death from any cause. The percentage of participants who died was reported.

Time frame:
From Baseline until time of event (median of 11 years)
Reported as:
Number · percentage of participants
Percentage of Participants With OS Events Compared to Observation: 11-Year Median Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year ArmHerceptin 2-Year Arm
Percentage of Participants With OS Events Compared to Observation: 11-Year Median Follow-Up23.918.818.4
Statistical analysis
  • Observation Arm vs Herceptin 1-Year Arm · Hazard ratio (hr): 0.74 · 95% CI 0.64 to 0.86HR for Herceptin 1-Year Arm versus Observation Arm.
  • Observation Arm vs Herceptin 2-Year Arm · Hazard ratio (hr): 0.72 · 95% CI 0.62 to 0.83HR for Herceptin 2-Year Arm versus Observation Arm.
SecondaryOS Rate According to Kaplan-Meier Analysis Compared to Observation: 11-Year Median Follow-Up

OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with an 11-year median follow-up for OS events.

Time frame:
Years 3, 5, 7, 9, 10, 11, 12
Reported as:
Number · percentage of participants
OS Rate According to Kaplan-Meier Analysis Compared to Observation: 11-Year Median Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year ArmHerceptin 2-Year Arm
Year 390.7 (89.3 to 92.1)92.7 (91.5 to 94.0)94.4 (93.3 to 95.6)
Year 584.5 (82.8 to 86.3)86.9 (85.2 to 88.5)88.7 (87.2 to 90.3)
Year 779.4 (77.4 to 81.4)83.8 (82.0 to 85.6)84.7 (82.9 to 86.4)
Year 976.5 (74.4 to 78.6)81.9 (80.0 to 83.8)81.8 (80.0 to 83.7)
Year 1075.0 (72.9 to 77.2)80.7 (78.8 to 82.6)81.0 (79.0 to 82.9)
Year 1173.7 (71.5 to 76.0)80.0 (78.1 to 82.0)80.3 (78.3 to 82.3)
Year 1272.9 (70.4 to 75.3)79.4 (77.3 to 81.5)79.5 (77.4 to 81.7)
SecondaryPercentage of Participants With OS Events in 1-Year Versus 2-Year Herceptin: 11-Year Median Follow-Up

OS events referred to death from any cause. The percentage of participants who died was reported.

Time frame:
From Baseline until time of event (median of 11 years)
Reported as:
Number · percentage of participants
Percentage of Participants With OS Events in 1-Year Versus 2-Year Herceptin: 11-Year Median Follow-Up
percentage of participantsHerceptin 1-Year ArmHerceptin 2-Year Arm
Percentage of Participants With OS Events in 1-Year Versus 2-Year Herceptin: 11-Year Median Follow-Up14.714.9
Statistical analysis
  • Herceptin 1-Year Arm vs Herceptin 2-Year Arm · Log Rank · p = 0.9156 · Hazard ratio (hr): 1.01 · 95% CI 0.84 to 1.21HR for Herceptin 2-Year Arm versus Herceptin 1-Year Arm.
SecondaryOS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 11-Year Median Follow-Up

OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with an 11-year median follow-up for OS events.

Time frame:
Years 3, 5, 7, 9, 10, 11, 12
Reported as:
Number · percentage of participants
OS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 11-Year Median Follow-Up
percentage of participantsHerceptin 1-Year ArmHerceptin 2-Year Arm
Year 396.5 (95.6 to 97.4)97.4 (96.6 to 98.2)
Year 591.4 (90.0 to 92.8)92.6 (91.2 to 93.9)
Year 788.6 (87.0 to 90.2)88.7 (87.1 to 90.3)
Year 986.7 (85.0 to 88.5)85.9 (84.2 to 87.7)
Year 1085.4 (83.6 to 87.2)85.1 (83.3 to 86.9)
Year 1184.7 (82.9 to 86.6)84.4 (82.5 to 86.2)
Year 1284.1 (82.1 to 86.1)83.6 (81.5 to 85.6)
SecondaryPercentage of Participants With Recurrence-Free Survival (RFS) Events Compared to Observation: 8-Year Median Follow-Up

RFS events included local, regional, or distant tumor recurrence. The percentage of participants with at least one RFS event was reported.

Time frame:
From Baseline until time of event (median of 8 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Recurrence-Free Survival (RFS) Events Compared to Observation: 8-Year Median Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year ArmHerceptin 2-Year Arm
Percentage of Participants With Recurrence-Free Survival (RFS) Events Compared to Observation: 8-Year Median Follow-Up29.823.422.6
Statistical analysis
  • Observation Arm vs Herceptin 1-Year Arm · Log Rank · p = <0.0001
  • Observation Arm vs Herceptin 1-Year Arm · Hazard ratio (hr): 0.73 · 95% CI 0.64 to 0.83HR for Herceptin 1-Year Arm versus Observation Arm.
  • Observation Arm vs Herceptin 2-Year Arm · Log Rank · p = <0.0001
  • Observation Arm vs Herceptin 2-Year Arm · Hazard ratio (hr): 0.69 · 95% CI 0.61 to 0.79HR for Herceptin 2-Year Arm versus Observation Arm.
SecondaryRFS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up

RFS events included local, regional, or distant tumor recurrence. The percentage of participants free of RFS events (i.e., the RFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.

Time frame:
Years 3, 5, 7, 8
Reported as:
Number · percentage of participants
RFS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year ArmHerceptin 2-Year Arm
Year 376.4 (74.3 to 78.4)82.7 (80.9 to 84.6)86.0 (84.3 to 87.6)
Year 571.9 (69.7 to 74.1)78.4 (76.4 to 80.4)79.9 (77.9 to 81.9)
Year 769.0 (66.7 to 71.3)75.7 (73.6 to 77.8)76.7 (74.6 to 78.8)
Year 868.4 (66.1 to 70.7)75.1 (72.9 to 77.2)75.8 (73.6 to 77.9)
SecondaryPercentage of Participants With RFS Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up

RFS events included local, regional, or distant tumor recurrence. The percentage of participants with at least one RFS event was reported.

Time frame:
From Baseline until time of event (median of 8 years)
Reported as:
Number · percentage of participants
Percentage of Participants With RFS Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up
percentage of participantsHerceptin 1-Year ArmHerceptin 2-Year Arm
Percentage of Participants With RFS Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up19.718.8
Statistical analysis
  • Herceptin 1-Year Arm vs Herceptin 2-Year Arm · Log Rank · p = 0.4755 · Hazard ratio (hr): 0.94 · 95% CI 0.80 to 1.11HR for Herceptin 2-Year Arm versus Herceptin 1-Year Arm.
SecondaryRFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up

RFS events included local, regional, or distant tumor recurrence. The percentage of participants free of RFS events (i.e., the RFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.

Time frame:
Years 3, 5, 7, 8
Reported as:
Number · percentage of participants
RFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up
percentage of participantsHerceptin 1-Year ArmHerceptin 2-Year Arm
Year 387.7 (86.0 to 89.3)90.9 (89.4 to 92.3)
Year 583.1 (81.2 to 85.0)84.5 (82.7 to 86.4)
Year 780.2 (78.2 to 82.3)81.3 (79.3 to 83.2)
Year 879.6 (77.5 to 81.6)80.3 (78.2 to 82.3)
SecondaryPercentage of Participants With Distant Disease-Free Survival (DDFS) Events Compared to Observation: 8-Year Median Follow-Up

DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants with at least one DDFS event was reported.

Time frame:
From Baseline until time of event (median of 8 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Distant Disease-Free Survival (DDFS) Events Compared to Observation: 8-Year Median Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year ArmHerceptin 2-Year Arm
Percentage of Participants With Distant Disease-Free Survival (DDFS) Events Compared to Observation: 8-Year Median Follow-Up28.823.423.2
Statistical analysis
  • Observation Arm vs Herceptin 1-Year Arm · Log Rank · p = <0.0001
  • Observation Arm vs Herceptin 1-Year Arm · Hazard ratio (hr): 0.76 · 95% CI 0.67 to 0.87HR for Herceptin 1-Year Arm versus Observation Arm.
  • Observation Arm vs Herceptin 2-Year Arm · Log Rank · p = <0.0001
  • Observation Arm vs Herceptin 2-Year Arm · Hazard ratio (hr): 0.75 · 95% CI 0.65 to 0.85HR for Herceptin 2-Year Arm versus Observation Arm.
SecondaryDDFS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up

DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants free of DDFS events (i.e., the DDFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.

Time frame:
Years 3, 5, 7, 8
Reported as:
Number · percentage of participants
DDFS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year ArmHerceptin 2-Year Arm
Year 378.6 (76.6 to 80.6)84.4 (82.7 to 86.2)85.9 (84.2 to 87.6)
Year 574.2 (72.1 to 76.4)79.6 (77.6 to 81.6)80.2 (78.2 to 82.1)
Year 770.8 (68.6 to 73.1)76.7 (74.6 to 78.8)76.7 (74.6 to 78.8)
Year 869.6 (67.3 to 71.9)75.5 (73.4 to 77.6)75.6 (73.4 to 77.7)
SecondaryPercentage of Participants With DDFS Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up

DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants with at least one DDFS event was reported.

Time frame:
From Baseline until time of event (median of 8 years)
Reported as:
Number · percentage of participants
Percentage of Participants With DDFS Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up
percentage of participantsHerceptin 1-Year ArmHerceptin 2-Year Arm
Percentage of Participants With DDFS Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up19.519.5
Statistical analysis
  • Herceptin 1-Year Arm vs Herceptin 2-Year Arm · Log Rank · p = 0.9626 · Hazard ratio (hr): 1.00 · 95% CI 0.85 to 1.17HR for Herceptin 2-Year Arm versus Herceptin 1-Year Arm.
SecondaryDDFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up

DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants free of DDFS events (i.e., the DDFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.

Time frame:
Years 3, 5, 7, 8
Reported as:
Number · percentage of participants
DDFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up
percentage of participantsHerceptin 1-Year ArmHerceptin 2-Year Arm
Year 389.4 (87.9 to 91.0)90.8 (89.4 to 92.2)
Year 584.5 (82.7 to 86.3)84.7 (82.9 to 86.5)
Year 781.4 (79.5 to 83.4)81.1 (79.1 to 83.1)
Year 880.1 (78.1 to 82.2)79.9 (77.8 to 81.9)
SecondaryPercentage of Participants With Tumor Recurrence (TR) Compared to Observation: 8-Year Median Follow-Up

The percentage of participants with TR of the present breast cancer was reported. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy.

Time frame:
From Baseline until time of event (median of 8 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Tumor Recurrence (TR) Compared to Observation: 8-Year Median Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year ArmHerceptin 2-Year Arm
Percentage of Participants With Tumor Recurrence (TR) Compared to Observation: 8-Year Median Follow-Up29.823.422.6
Statistical analysis
  • Observation Arm vs Herceptin 1-Year Arm · Log Rank · p = <0.0001
  • Observation Arm vs Herceptin 1-Year Arm · Hazard ratio (hr): 0.73 · 95% CI 0.64 to 0.83HR for Herceptin 1-Year Arm versus Observation Arm.
  • Observation Arm vs Herceptin 2-Year Arm · Log Rank · p = <0.0001
  • Observation Arm vs Herceptin 2-Year Arm · Hazard ratio (hr): 0.69 · 95% CI 0.61 to 0.79HR for Herceptin 2-Year Arm versus Observation Arm.
SecondaryTR-Free Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up

The percentage of participants without TR of the present breast cancer (i.e., the TR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy.

Time frame:
Years 3, 5, 7, 8
Reported as:
Number · percentage of participants
TR-Free Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year ArmHerceptin 2-Year Arm
Year 376.5 (74.4 to 78.5)82.8 (81.0 to 84.6)86.1 (84.4 to 87.7)
Year 572.1 (69.9 to 74.3)78.6 (76.6 to 80.6)80.1 (78.2 to 82.1)
Year 769.2 (67.0 to 71.5)75.9 (73.9 to 78.0)77.0 (75.0 to 79.1)
Year 868.6 (66.4 to 70.9)75.3 (73.2 to 77.4)76.2 (74.1 to 78.3)
SecondaryPercentage of Participants With TR in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up

The percentage of participants with TR of the present breast cancer was reported. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy.

Time frame:
From Baseline until time of event (median of 8 years)
Reported as:
Number · percentage of participants
Percentage of Participants With TR in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up
percentage of participantsHerceptin 1-Year ArmHerceptin 2-Year Arm
Percentage of Participants With TR in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up19.718.8
Statistical analysis
  • Herceptin 1-Year Arm vs Herceptin 2-Year Arm · Log Rank · p = 0.4500 · Hazard ratio (hr): 0.94 · 95% CI 0.80 to 1.10HR for Herceptin 2-Year Arm versus Herceptin 1-Year Arm.
SecondaryTR-Free Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up

The percentage of participants without TR of the present breast cancer (i.e., the TR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy.

Time frame:
Years 3, 5, 7, 8
Reported as:
Number · percentage of participants
TR-Free Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up
percentage of participantsHerceptin 1-Year ArmHerceptin 2-Year Arm
Year 387.7 (86.1 to 89.4)90.9 (89.5 to 92.4)
Year 583.2 (81.3 to 85.1)84.7 (82.9 to 86.5)
Year 780.4 (78.4 to 82.4)81.5 (79.6 to 83.5)
Year 879.8 (77.7 to 81.8)80.6 (78.6 to 82.6)
SecondaryPercentage of Participants With Distant Tumor Recurrence (DTR) Compared to Observation: 8-Year Median Follow-Up

The percentage of participants with DTR was reported. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy.

Time frame:
From Baseline until time of event (median of 8 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Distant Tumor Recurrence (DTR) Compared to Observation: 8-Year Median Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year ArmHerceptin 2-Year Arm
Percentage of Participants With Distant Tumor Recurrence (DTR) Compared to Observation: 8-Year Median Follow-Up25.319.418.8
Statistical analysis
  • Observation Arm vs Herceptin 1-Year Arm · Log Rank · p = <0.0001
  • Observation Arm vs Herceptin 1-Year Arm · Hazard ratio (hr): 0.72 · 95% CI 0.62 to 0.83HR for Herceptin 1-Year Arm versus Observation Arm.
  • Observation Arm vs Herceptin 2-Year Arm · Log Rank · p = <0.0001
  • Observation Arm vs Herceptin 2-Year Arm · Hazard ratio (hr): 0.69 · 95% CI 0.59 to 0.79HR for Herceptin 2-Year Arm versus Observation Arm.
SecondaryDTR-Free Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up

The percentage of participants without DTR (i.e., the DTR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy.

Time frame:
Years 3, 5, 7, 8
Reported as:
Number · percentage of participants
DTR-Free Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year ArmHerceptin 2-Year Arm
Year 379.8 (77.8 to 81.7)85.9 (84.2 to 87.6)88.1 (86.5 to 89.6)
Year 576.5 (74.4 to 78.5)82.1 (80.2 to 84.0)83.4 (81.5 to 85.2)
Year 774.0 (71.8 to 76.1)80.1 (78.2 to 82.1)80.7 (78.8 to 82.6)
Year 873.3 (71.1 to 75.5)79.5 (77.5 to 81.5)80.3 (78.3 to 82.2)
SecondaryPercentage of Participants With DTR in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up

The percentage of participants with DTR was reported. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy.

Time frame:
From Baseline until time of event (median of 8 years)
Reported as:
Number · percentage of participants
Percentage of Participants With DTR in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up
percentage of participantsHerceptin 1-Year ArmHerceptin 2-Year Arm
Percentage of Participants With DTR in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up15.515.1
Statistical analysis
  • Herceptin 1-Year Arm vs Herceptin 2-Year Arm · Log Rank · p = 0.6823 · Hazard ratio (hr): 0.96 · 95% CI 0.80 to 1.15HR for Herceptin 2-Year Arm versus Herceptin 1-Year Arm.
SecondaryDTR-Free Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up

The percentage of participants without DTR (i.e., the DTR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy.

Time frame:
Years 3, 5, 7, 8
Reported as:
Number · percentage of participants
DTR-Free Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up
percentage of participantsHerceptin 1-Year ArmHerceptin 2-Year Arm
Year 390.5 (89.0 to 91.9)92.4 (91.1 to 93.8)
Year 586.7 (85.0 to 88.4)87.5 (85.8 to 89.2)
Year 784.6 (82.8 to 86.4)84.9 (83.1 to 86.7)
Year 883.9 (82.1 to 85.8)84.4 (82.6 to 86.3)
SecondaryPercentage of Participants With Restricted Disease-Free Survival (RDFS) Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up

RDFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer, or death from any cause. The percentage of participants with at least one RDFS event was reported.

Time frame:
From Baseline until time of event (median of 8 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Restricted Disease-Free Survival (RDFS) Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up
percentage of participantsHerceptin 1-Year ArmHerceptin 2-Year Arm
Percentage of Participants With Restricted Disease-Free Survival (RDFS) Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up22.221.9
Statistical analysis
  • Herceptin 1-Year Arm vs Herceptin 2-Year Arm · Log Rank · p = 0.7251 · Hazard ratio (hr): 0.97 · 95% CI 0.84 to 1.13HR for Herceptin 2-Year Arm versus Herceptin 1-Year Arm.
SecondaryRDFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up

RDFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer, or death from any cause. The percentage of participants free of RDFS events (i.e., the RDFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.

Time frame:
Years 3, 5, 7, 8
Reported as:
Number · percentage of participants
RDFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up
percentage of participantsHerceptin 1-Year ArmHerceptin 2-Year Arm
Year 387.3 (85.6 to 89.0)89.9 (88.4 to 91.4)
Year 581.9 (79.9 to 83.8)83.0 (81.1 to 84.9)
Year 778.5 (76.4 to 80.6)78.9 (76.9 to 81.0)
Year 877.2 (75.1 to 79.3)77.7 (75.5 to 79.8)
SecondaryPercentage of Participants With Primary Cardiac Endpoint Events Compared to Observation: 10-Year Maximum Follow-Up

Primary cardiac endpoint events included the occurrence of any of the following between randomization and new therapy for recurrent disease: symptomatic New York Heart Association (NYHA) Class III or IV congestive heart failure (CHF) confirmed by a cardiologist with a drop in left ventricular ejection fraction (LVEF) at least 10 percentage points from Baseline and to a value less than (\<) 50%, and documentation of definite or probable cardiac death. Definite cardiac death included CHF, myocardial infarction, or primary arrhythmia. Probable cardiac death included unexpected sudden death within 24 hours of a cardiac event (syncope, cardiac arrest, chest pain, infarction, arrhythmia) without documented etiology. The percentage of participants with at least one primary cardiac endpoint event was reported. The 95% CI was calculated by the Pearson-Clopper method for a one-sample binomial.

Time frame:
From Baseline until time of event (maximum up to 10 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Primary Cardiac Endpoint Events Compared to Observation: 10-Year Maximum Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year ArmHerceptin 2-Year Arm
Percentage of Participants With Primary Cardiac Endpoint Events Compared to Observation: 10-Year Maximum Follow-Up0.11 (0.01 to 0.41)1.07 (0.64 to 1.69)1.02 (0.59 to 1.62)
SecondaryPercentage of Participants With Secondary Cardiac Endpoint Events Compared to Observation: 10-Year Maximum Follow-Up

Secondary cardiac endpoint events included NYHA Class I or II CHF with a drop in LVEF measured by multiple-gated acquisition or electrocardiogram, unless the subsequent assessment of LVEF indicated a return to levels that did not meet the definition of a significant LVEF drop. A significant LVEF drop was defined as an absolute reduction of at least 10 percentage points from Baseline and to a value \<50%. The percentage of participants with at least one secondary cardiac endpoint event was reported, excluding those with both a primary and secondary cardiac endpoint event. The 95% CI was calculated by the Pearson-Clopper method for a one-sample binomial.

Time frame:
From Baseline until time of event (maximum up to 10 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Secondary Cardiac Endpoint Events Compared to Observation: 10-Year Maximum Follow-Up
percentage of participantsObservation ArmHerceptin 1-Year ArmHerceptin 2-Year Arm
Percentage of Participants With Secondary Cardiac Endpoint Events Compared to Observation: 10-Year Maximum Follow-Up0.86 (0.48 to 1.41)4.40 (3.47 to 5.49)7.29 (6.09 to 8.64)

Adverse events

Collected over From Baseline until end of treatment (maximum up to 2 years) with the exception of cardiac/cardiovascular events, second primary malignancies, pregnancies, and Herceptin-related adverse events (maximum up to 10 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Observation Arm—143/1,744 (8.2%)1,076/1,744 (61.7%)
Herceptin 1-Year Arm—269/1,682 (16%)1,389/1,682 (82.6%)
Herceptin 2-Year Arm—344/1,673 (20.6%)1,440/1,673 (86.1%)
Most frequent serious events
Showing 10 of 398
Most frequent serious events
EventObservation ArmHerceptin 1-Year ArmHerceptin 2-Year Arm
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)9/174427/168236/1673
PregnancyPregnancy, puerperium and perinatal conditions11/174422/168229/1673
Cardiac failure congestiveCardiac disorders1/174419/168224/1673
Device related infectionInfections and infestations2/17449/16828/1673
Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/17448/16828/1673
ErysipelasInfections and infestations1/17448/16824/1673
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/17441/16827/1673
Endometrial hyperplasiaReproductive system and breast disorders3/17444/16827/1673
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/17447/16821/1673
PyrexiaGeneral disorders0/17443/16826/1673
Most frequent other events
Showing 10 of 32
Most frequent other events
EventObservation ArmHerceptin 1-Year ArmHerceptin 2-Year Arm
NasopharyngitisInfections and infestations65/1744187/1682269/1673
HeadacheNervous system disorders72/1744201/1682250/1673
FatigueGeneral disorders83/1744198/1682246/1673
ArthralgiaMusculoskeletal and connective tissue disorders152/1744225/1682246/1673
DiarrhoeaGastrointestinal disorders22/1744155/1682180/1673
Hot flushVascular disorders130/1744166/1682159/1673
NauseaGastrointestinal disorders37/1744134/1682157/1673
CoughRespiratory, thoracic and mediastinal disorders62/1744116/1682147/1673
Back painMusculoskeletal and connective tissue disorders106/1744146/1682137/1673
PyrexiaGeneral disorders12/1744116/1682145/1673

Baseline characteristics

Full Analysis Set (FAS) Population: All enrolled/randomized participants who had an available signed Informed Consent Form.

Age, Continuous
Age, Continuous(years)Observation ArmHerceptin 1-Year ArmHerceptin 2-Year ArmTotal
Mean49.2 ± 10.0849.0 ± 10.0649.2 ± 10.0949.1 ± 10.08
Sex: Female, Male
Sex: Female, Male(Participants)Observation ArmHerceptin 1-Year ArmHerceptin 2-Year ArmTotal
Female1697170217005099
Male0000
08

Study locations

203 sites
  • Hospital Aleman de Buenos Aires
    Buenos Aires, 1118, Argentina
  • Saint John of God Hospital
    Geelong, Australian Capital Territory 3220, Australia
  • Toowoomba Hospital
    Toowoomba, Queensland 4350, Australia
  • Andrew Love Cancer Centre
    Geelong, Victoria 3220, Australia
  • Mount Hospital
    Perth, Western Australia 6000, Australia
  • Landeskrankenhaus Feldkirch
    Feldkirch-Tisis, 6807, Austria
  • Innsbruck Universitaetsklinik
    Innsbruck, A-6020, Austria
  • Landeskrankenhaus Klagenfurt
    Klagenfurt, 9026, Austria
  • St. Vincent's Hospital
    Linz Donau, A-4010, Austria
  • Landeskrankenanstalten - Salzburg
    Salzburg, A-5020, Austria
  • Landeskrankenhaus St. Poelten
    St. Poelten, 3100, Austria
  • Universitaetsklinik fuer Innere Medizin I
    Vienna, 1090, Austria
  • Wilhelminenspital der Stadt Wien
    Vienna, A-1160, Austria
  • LKH Villach
    Villach, 9500, Austria
  • LKH Voecklabruck
    Voecklabruck, 4840, Austria
  • A. oe. Krankenhaus Wiener Neustadt
    Wiener Neustadt, A-2700, Austria
  • Ziekenhuis Netwerk Antwerpen Middelheim
    Antwerp, 2020, Belgium
  • Reseau Hospitalier De Medecine Sociale
    Baudour, 7331, Belgium
  • Hopital Universitaire Erasme
    Brussels, 1070, Belgium
  • Academisch Ziekenhuis der Vrije Universiteit Brussel
    Brussels, 1090, Belgium
  • Institut Jules Bordet
    Brussels, B-1000, Belgium
  • Centre Hospitalier Notre Dame - Reine Fabiola
    Charleroi, 6000, Belgium
  • Cazk Groeninghe - Campus St-Niklaas
    Kortrijk, B-8500, Belgium
  • Centre Hospitalier Universitaire de Tivoli
    La Louviere, 7100, Belgium
  • U.Z. Gasthuisberg
    Leuven, B-3000, Belgium
  • Clinique Saint-Joseph
    Liege, B 4000, Belgium
  • CHU Liege - Domaine Universitaire du Sart Tilman
    Liege, B-4000, Belgium
  • Clinique Sainte Elisabeth
    Namur, 5000, Belgium
  • Hospital Serruys Ziekenhuis
    Oostende, 8400, Belgium
  • Centre Hospitalier Peltzer-La Tourelle
    Verviers, B-4800, Belgium
  • Porto Alegre Hospital
    Porto Alegre, Rio Grande do Sul 90035-003, Brazil
  • Hospital Sao Lucas da PUCRS
    Porto Alegre, 90610-000, Brazil
  • Hospital Santa Rita
    Porto Alegre, 91330-490, Brazil
  • Instituto Nacional de Cancer
    Rio de Janeiro, 20560-120, Brazil
  • Faculdade De Medicina Do ABC
    Santo Andre, 09060-650, Brazil
  • Tom Baker Cancer Centre - Calgary
    Calgary, Alberta T2N 4N2, Canada
  • British Columbia Cancer Agency - Centre for the Southern Interior
    Kelowna, British Columbia V1Y 5L3, Canada
  • Fraser Valley Cancer Centre at British Columbia Cancer Agency
    Surrey, British Columbia V3V 1Z2, Canada
  • British Columbia Cancer Agency - Vancouver Cancer Centre
    Vancouver, British Columbia V5Z 4E6, Canada
  • British Columbia Cancer Agency - Vancouver Island Cancer Centre
    Victoria, British Columbia V8R 6V5, Canada
  • CancerCare Manitoba
    Winnipeg, Manitoba R2H 2A6, Canada
  • Royal Victoria Hospital of Barrie
    Barrie, Ontario L4M 6M2, Canada
  • Margaret and Charles Juravinski Cancer Centre
    Hamilton, Ontario L8V 5C2, Canada
  • Trillium Health Centre - Mississauga Site
    Mississauga, Ontario L5B 1B8, Canada
  • Algoma Regional Cancer Program at Sault Area Hospital
    Sault Sainte Marie, Ontario P6A 2C4, Canada
  • Hotel Dieu Health Sciences Hospital - Niagara
    St. Catharines, Ontario L2R 5K3, Canada
  • Toronto East General Hospital
    Toronto, Ontario M4C 3E7, Canada
  • Mount Sinai Hospital - Toronto
    Toronto, Ontario M5G 1X5, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
  • Windsor Regional Cancer Centre at Windsor Regional Hospital
    Windsor, Ontario N8W 2X3, Canada
  • Prince Edward Island Cancer Centre at Queen Elizabeth Hospital
    Charlottetown, Prince Edward Island C1A 8T5, Canada
  • Hopital du Saint-Sacrement, Quebec
    Quebec City, Quebec G1S 4L8, Canada
  • Allan Blair Cancer Centre at Pasqua Hospital
    Regina, Saskatchewan S4T 7T1, Canada
  • Saskatoon Cancer Centre at the University of Saskatchewan
    Saskatoon, Saskatchewan S7N 4H4, Canada
  • Fundacion Arturo Lopez Perez
    Santiago, 29, Chile
  • Hospital Clinico San Borja Arriaran
    Santiago, Chile
  • Hospital Dr. Sotero Del Rio
    Santiago, Chile
  • Hospital Militar
    Santiago, Chile
  • Instituto Nacional Del Cancer
    Santiago, Chile
  • Queen Mary Hospital
    Hong Kong, China
  • Tuen Mun Hospital
    Hong Kong, China
  • Tongji Medical University
    Wuhan, 430030, China
  • Instituto Nacional De Cancerologia
    Bogota, Colombia
  • Clinical Hospital Center Split
    Split, 21000, Croatia
  • Centralsygehus I Esbjerg
    Esbjerg, 6700, Denmark
  • Herning Central Hospital
    Herning, 7400, Denmark
  • Hillerod Hospital
    Hillerod, 3400, Denmark
  • Centralsygehuset I Naestved
    Naestved, 4700, Denmark
  • Sonderborg Sygehus
    Sonderborg, 6400, Denmark
  • Centre Regional Francois Baclesse
    Caen, 14076, France
  • Centre Hospital Regional Universitaire de Limoges
    Limoges, 87042, France
  • Hopital Clinique Claude Bernard
    Metz, 57072, France
  • Charite - Campus Charite Mitte
    Berlin, D-10117, Germany
  • Evangelisches Bethesda Krankenhaus GmbH
    Essen, D-45355, Germany
  • Universitaetsklinikum Freiburg
    Freiburg, D-79106, Germany
  • Martin Luther Universitaet
    Halle, D-06097, Germany
  • Henriettenstiftung Krankenhaus
    Hanover, D-30559, Germany
  • Universitaets-Hautklinik Heidelberg
    Heidelberg, D-69115, Germany
  • St. Vincentius-Kliniken
    Karlsruhe, D-76137, Germany
  • University Hospital Schleswig-Holstein - Kiel Campus
    Kiel, D-24105, Germany
  • Kreiskrankenhaus Leonberg - Frauenklinik
    Leonberg, D-71229, Germany
  • Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg
    Magdeburg, D-39120, Germany
  • Frauenklinik Vom Roten Kreuz
    Munich, 80637, Germany
  • Klinikum Rechts Der Isar - Technische Universitaet Muenchen
    Munich, D-81675, Germany
  • Frauenklinik - Universitaetsklinikum Rostock am Klinikum Sudstadt
    Rostock, D-18059, Germany
  • Universitaet Ulm
    Ulm, D-89075, Germany
  • Dr. Horst-Schmidt-Kliniken
    Wiesbaden, D-65199, Germany
  • University of Crete School of Medicine
    Heraklion, Crete 71110, Greece
  • Evaggelismos Hospital
    Athens, 10676, Greece
  • Centro Medico
    Guatemala City, 01010, Guatemala
  • Hospital Roosevelt
    Guatemala City, 01010, Guatemala
  • Prince of Wales Hospital
    Shatin, New Territories, Hong Kong
  • Semmelweis University
    Budapest, 1082, Hungary
  • National Institute of Oncology
    Budapest, 1122, Hungary
  • Fovarosi Onkormanyzat Szent Margit Korhaz, Okologia
    Budapest, H-1032, Hungary
  • Cork University Hospital
    Cork, Ireland
  • Sieff Hospital
    Safed, 13110, Israel
  • Ospedale San Lazzaro
    Alba, 12051, Italy
  • Ospedale Presenti Fenaroli
    Alzano-Lombardo, 24022, Italy
  • Centro di Riferimento Oncologico - Aviano
    Aviano, 33081, Italy

Showing the first 100 of 203 sites across 33 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Jahanzeb M. Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer. 2008 Aug;8(4):324-33. doi: 10.3816/CBC.2008.n.037. PubMed 18757259 ↗
  • Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K. The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. Breast Cancer Res Treat. 2008 Jun;109(3):559-66. doi: 10.1007/s10549-007-9679-4. Epub 2007 Jul 28. PubMed 17661170 ↗
  • Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R; Herceptin Adjuvant (HERA) Trial Study Team. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011 Mar;12(3):236-44. doi: 10.1016/S1470-2045(11)70033-X. Epub 2011 Feb 25. PubMed 21354370 ↗
  • Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, Climent MA, Rechberger E, Liu WT, Toi M, Coombes RC, Dodwell D, Pagani O, Madrid J, Hall M, Chen SC, Focan C, Muschol M, van Veldhuisen DJ, Piccart-Gebhart MJ. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol. 2010 Jul 20;28(21):3422-8. doi: 10.1200/JCO.2009.26.0463. Epub 2010 Jun 7. PubMed 20530280 ↗
  • Dowsett M, Procter M, McCaskill-Stevens W, de Azambuja E, Dafni U, Rueschoff J, Jordan B, Dolci S, Abramovitz M, Stoss O, Viale G, Gelber RD, Piccart-Gebhart M, Leyland-Jones B. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol. 2009 Jun 20;27(18):2962-9. doi: 10.1200/JCO.2008.19.7939. Epub 2009 Apr 13. PubMed 19364966 ↗
  • Untch M, Gelber RD, Jackisch C, Procter M, Baselga J, Bell R, Cameron D, Bari M, Smith I, Leyland-Jones B, de Azambuja E, Wermuth P, Khasanov R, Feng-Yi F, Constantin C, Mayordomo JI, Su CH, Yu SY, Lluch A, Senkus-Konefka E, Price C, Haslbauer F, Suarez Sahui T, Srimuninnimit V, Colleoni M, Coates AS, Piccart-Gebhart MJ, Goldhirsch A; HERA Study Team. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol. 2008 Jun;19(6):1090-6. doi: 10.1093/annonc/mdn005. Epub 2008 Feb 21. PubMed 18296421 ↗
  • McCaskill-Stevens W, Procter M, Goodbrand J, et al.: Disease-free survival according to local immunohistochemistry for HER2 and central fluorescence in situ hydridization for patients treated with adjuvant chemotherapy with and without trastuzumab in the HERA (BIG 01-01) trial. [Abstract] Breast Cancer Res Treat 106 (1): A-71, S18, 2007.
  • Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sanchez Rovira P, Piccart-Gebhart MJ; HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007 Jan 6;369(9555):29-36. doi: 10.1016/S0140-6736(07)60028-2. PubMed 17208639 ↗
  • Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JG, Ageev FT, Hitre E, Groetz J, Iwata H, Knap M, Gnant M, Muehlbauer S, Spence A, Gelber RD, Piccart-Gebhart MJ. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007 Sep 1;25(25):3859-65. doi: 10.1200/JCO.2006.09.1611. Epub 2007 Jul 23. PubMed 17646669 ↗
  • Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005 Oct 20;353(16):1659-72. doi: 10.1056/NEJMoa052306. PubMed 16236737 ↗
  • Yerushalmi R, Dong B, Chapman JW, Goss PE, Pollak MN, Burnell MJ, Levine MN, Bramwell VHC, Pritchard KI, Whelan TJ, Ingle JN, Shepherd LE, Parulekar WR, Han L, Ding K, Gelmon KA. Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials. Ann Oncol. 2017 Jul 1;28(7):1560-1568. doi: 10.1093/annonc/mdx152. PubMed 28379421 ↗
  • Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G Jr, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C; Herceptin Adjuvant (HERA) Trial Study Team. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017 Mar 25;389(10075):1195-1205. doi: 10.1016/S0140-6736(16)32616-2. Epub 2017 Feb 17. Erratum In: Lancet. 2019 Mar 16;393(10176):1100. doi: 10.1016/S0140-6736(18)32771-5. PubMed 28215665 ↗
  • Loi S, Dafni U, Karlis D, Polydoropoulou V, Young BM, Willis S, Long B, de Azambuja E, Sotiriou C, Viale G, Ruschoff J, Piccart MJ, Dowsett M, Michiels S, Leyland-Jones B. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial. JAMA Oncol. 2016 Aug 1;2(8):1040-7. doi: 10.1001/jamaoncol.2016.0339. PubMed 27100299 ↗
  • O'Sullivan CC, Bradbury I, Campbell C, Spielmann M, Perez EA, Joensuu H, Costantino JP, Delaloge S, Rastogi P, Zardavas D, Ballman KV, Holmes E, de Azambuja E, Piccart-Gebhart M, Zujewski JA, Gelber RD. Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors </= 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. J Clin Oncol. 2015 Aug 20;33(24):2600-8. doi: 10.1200/JCO.2015.60.8620. Epub 2015 Jun 22. PubMed 26101239 ↗
  • de Azambuja E, Procter MJ, van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O, Steinseifer J, Untch M, Smith IE, Gianni L, Baselga J, Jackisch C, Cameron DA, Bell R, Leyland-Jones B, Dowsett M, Gelber RD, Piccart-Gebhart MJ, Suter TM. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). J Clin Oncol. 2014 Jul 10;32(20):2159-65. doi: 10.1200/JCO.2013.53.9288. Epub 2014 Jun 9. PubMed 24912899 ↗
  • Zabaglo L, Stoss O, Ruschoff J, Zielinski D, Salter J, Arfi M, Bradbury I, Dafni U, Piccart-Gebhart M, Procter M, Dowsett M; HERA Trial Study Team. HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab. Ann Oncol. 2013 Nov;24(11):2761-6. doi: 10.1093/annonc/mdt275. Epub 2013 Jul 25. PubMed 23894039 ↗
  • Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, McFadden E, Dowsett M, Untch M, Gianni L, Bell R, Kohne CH, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J; Herceptin Adjuvant (HERA) Trial Study Team. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013 Sep 21;382(9897):1021-8. doi: 10.1016/S0140-6736(13)61094-6. Epub 2013 Jul 18. PubMed 23871490 ↗
  • Metzger-Filho O, Procter M, de Azambuja E, Leyland-Jones B, Gelber RD, Dowsett M, Loi S, Saini KS, Cameron D, Untch M, Smith I, Gianni L, Baselga J, Jackisch C, Bell R, Sotiriou C, Viale G, Piccart-Gebhart M. Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. J Clin Oncol. 2013 Jun 1;31(16):1954-60. doi: 10.1200/JCO.2012.46.2440. Epub 2013 Apr 15. PubMed 23589556 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2001, a primary completion of Mar 2005 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 12 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2002
First posted
Jan 27, 2003
Start
Nov 2001
Primary completionActual
Mar 2005
CompletionActual
Jun 2015
Results first posted
Apr 27, 2017
Last update
Apr 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00045032
Lead sponsor
Hoffmann-La Roche
Collaborators
Breast International Group, European Organisation for Research and Treatment of Cancer - EORTC, NCIC Clinical Trials Group, ETOP IBCSG Partners Foundation
Responsible party
Sponsor
First posted
Jan 27, 2003
Start date
Nov 2001
Primary completion
Mar 2005
Completion
Jun 2015
Results posted
Apr 27, 2017
Last update
Apr 27, 2017

Study contacts

Martine J. Piccart-Gebhart, MD, PhD
study chair · Jules Bordet Institute
Robert E. Coleman, MD, FRCP
study chair · Cancer Research Centre at Weston Park Hospital
Karen A. Gelmon, MD
study chair · British Columbia Cancer Agency
Kathleen I. Pritchard, MD
study chair · Toronto Sunnybrook Regional Cancer Centre
Olivia Pagani, MD
study chair · Ospedale Beata Vergine
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion